Alger

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.

Weatherbie Capital, LLC is an employee-owned investment management firm based in Boston, Massachusetts. Founded in December 1995 by Matthew Weatherbie, the firm specializes in managing growth equity portfolios, focusing primarily on small- and mid-cap companies in the United States. It provides investment services to a diverse clientele, including individuals, corporations, and various institutional entities such as pension plans and charitable organizations. Weatherbie Capital employs a fundamental, bottom-up research approach to identify and invest in attractive growth stocks, which has led to a strong record of performance over its two decades of operation. The firm also manages equity mutual funds and conducts in-house research to inform its investment decisions. In 2017, Weatherbie Capital became a subsidiary of Alger Associates Inc.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. The company specializes in the development of novel small-molecule antiviral therapeutics, utilizing a unique cell-free protein synthesizing systems platform for drug discovery. This approach enables the identification of small molecules that might be overlooked by conventional pharmaceutical screening methods. Prosetta is also engaged in partnerships with commercial and non-profit organizations to advance its research in oncology, neurodegenerative diseases, and infectious diseases. By focusing on small molecules that can modulate the assembly of multi-protein complexes within cells, Prosetta aims to address a broad range of human diseases and enhance therapeutic options for healthcare professionals.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on discovering and developing novel therapeutics for cancer and other serious diseases. Founded in 2011, the company has created a range of products targeting various signaling pathways involved in disease progression. Notable therapeutics include TP-0413, which addresses serum iron regulation in chronic inflammatory diseases; TP-0903, a dual-targeted agent for pancreatic cancer; and TP-0829, aimed at treating B-cell lymphomas and leukemia. Other developments include TP-0227, targeting pathways in endometrial carcinomas, and TP-1149, which aims to overcome resistance in myeloma cells. Tolero Pharmaceuticals is dedicated to improving patient outcomes through innovative approaches and has established a strategic partnership with MannKind Corporation to further its mission.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on discovering and developing novel therapeutics for cancer and other serious diseases. Founded in 2011, the company has created a range of products targeting various signaling pathways involved in disease progression. Notable therapeutics include TP-0413, which addresses serum iron regulation in chronic inflammatory diseases; TP-0903, a dual-targeted agent for pancreatic cancer; and TP-0829, aimed at treating B-cell lymphomas and leukemia. Other developments include TP-0227, targeting pathways in endometrial carcinomas, and TP-1149, which aims to overcome resistance in myeloma cells. Tolero Pharmaceuticals is dedicated to improving patient outcomes through innovative approaches and has established a strategic partnership with MannKind Corporation to further its mission.

ChoiceStream is a programmatic advertising partner that specializes in digital advertising services, focusing on cross-device branding and direct response campaigns for brands and agencies. The company oversees every stage of a campaign, from pre-launch planning to execution, ensuring efficient and scalable outreach to target audiences. By leveraging proprietary, poll-based data tailored to each campaign, ChoiceStream creates custom, targetable audiences and optimizes campaign performance in real-time. Its advanced machine-learning algorithms and a team of industry experts contribute to a high client retention rate, significantly exceeding industry norms. Through a combination of innovative technology and personalized support, ChoiceStream enhances ad relevance and improves overall campaign effectiveness.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.